| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23188500P | 2000-09-12 | 2000-09-12 | |
| US60231885 | 2000-09-12 | ||
| PCT/US2001/028297WO2002022133A1 (en) | 2000-09-12 | 2001-09-07 | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
| Publication Number | Publication Date |
|---|---|
| AU2001287157A1true AU2001287157A1 (en) | 2002-03-26 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001287157AAbandonedAU2001287157A1 (en) | 2000-09-12 | 2001-09-07 | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
| Country | Link |
|---|---|
| US (1) | US20050004007A1 (en) |
| AU (1) | AU2001287157A1 (en) |
| WO (1) | WO2002022133A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0102480D0 (en)* | 2001-01-31 | 2001-03-14 | Cyclacel Ltd | Marker |
| CN104274442A (en)* | 2001-02-19 | 2015-01-14 | 诺华股份有限公司 | Cancer treatment |
| EP2269609A3 (en)* | 2001-10-16 | 2012-07-11 | Sloan-Kettering Institute for Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain with SAHA |
| WO2003070188A2 (en)* | 2002-02-15 | 2003-08-28 | Sloan-Kettering Institute For Cancer Research | Method of treating trx mediated diseases |
| US20040132825A1 (en)* | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| US20060276547A1 (en)* | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
| US20070060614A1 (en)* | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
| US7148257B2 (en)* | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| CA2671976C (en)* | 2002-03-04 | 2016-05-10 | Merck Hdac Research, Llc. | Methods of inducing terminal differentiation |
| US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| JP2005530734A (en)* | 2002-04-15 | 2005-10-13 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Combination therapy for the treatment of cancer |
| JP2006501147A (en) | 2002-04-25 | 2006-01-12 | ユニバーシティー オブ コネティカット ヘルス センター | Use of heat shock proteins to improve the therapeutic efficacy of non-vaccine therapies |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20070060615A1 (en)* | 2003-02-18 | 2007-03-15 | University Of South Florida | Method of Modulating Apoptosis Through Modulation of E2F1 |
| JP2006520796A (en) | 2003-03-17 | 2006-09-14 | タケダ サン ディエゴ インコーポレイテッド | Histone deacetylase inhibitor |
| GB0315259D0 (en)* | 2003-06-30 | 2003-08-06 | Cyclacel Ltd | Use |
| ES2345775T3 (en)* | 2003-08-26 | 2010-10-01 | Merck Hdac Research, Llc | USE OF SAHA FOR THE TREATMENT OF MESOTELIOMA. |
| CN101856348A (en)* | 2003-08-29 | 2010-10-13 | 斯隆-凯特林癌症研究所 | Combination Approaches to Treating Cancer |
| EP1680123A1 (en)* | 2003-11-06 | 2006-07-19 | Cyclacel Limited | Use |
| JP2008524246A (en) | 2004-12-16 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | Histone deacetylase inhibitor |
| WO2006122319A2 (en) | 2005-05-11 | 2006-11-16 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CA2615105A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| AU2006311820A1 (en)* | 2005-11-04 | 2007-05-18 | Merck Sharp & Dohme Corp. | Methods of using SAHA and erlotinib for treating cancer |
| CA2627129A1 (en)* | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of using saha and bortezomib for treating cancer |
| GB0523040D0 (en)* | 2005-11-11 | 2005-12-21 | Cyclacel Ltd | Combination |
| EP1951307A2 (en)* | 2005-11-11 | 2008-08-06 | Cyclacel Limited | Combination of a cdk-inhibitor and a hdac-inhibitor |
| JP2010509221A (en)* | 2006-11-03 | 2010-03-25 | ユニバーシテイ・オブ・メリーランド，ボルテイモア | Methods of using SAHA and bortezomib to treat multiple myeloma |
| WO2010036404A2 (en)* | 2008-05-09 | 2010-04-01 | University Of Maryland, Baltimore | Novel retinamide retinoic acid metabolism blocking agents |
| US20130005747A1 (en)* | 2010-12-21 | 2013-01-03 | Cyclacel Limited | Method for selecting a cancer therapy |
| KR20180083902A (en) | 2015-11-18 | 2018-07-23 | 젠자임 코포레이션 | Biomarkers of polycystic kidney disease and uses thereof |
| JP7190425B2 (en) | 2016-08-23 | 2022-12-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Combination therapy for the treatment of hepatocellular carcinoma |
| EP3595725B1 (en) | 2017-03-16 | 2023-05-03 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
| CA3060243A1 (en) | 2017-04-17 | 2018-10-25 | The University Of Chicago | Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5880152A (en)* | 1995-10-06 | 1999-03-09 | Vertex Pharmaceuticals, Inc. | Butyrate prodrugs derived from lactic acid |
| US5821072A (en)* | 1996-02-20 | 1998-10-13 | Sloan-Kettering Institute For Cancer Research | Combinations of PKC inhibitors and therapaeutic agents for treating cancers |
| WO1997034598A1 (en)* | 1996-03-20 | 1997-09-25 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method of treating cancer using c-26 modified bryostatin |
| US6211239B1 (en)* | 1996-07-17 | 2001-04-03 | Centre International De Recherches Dermatologiques Galderma | Method for treating or preventing breast cancer or leukemia using 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN) |
| US6034074A (en)* | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
| US5922571A (en)* | 1997-03-06 | 1999-07-13 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a protein kinase C homolog |
| US6262116B1 (en)* | 1998-01-23 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Transcription therapy for cancers |
| US20020156033A1 (en)* | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
| US6509315B1 (en)* | 2000-04-07 | 2003-01-21 | The Trustees Of The University Of Pennsylvania | Didemnin analogs and fragments and methods of making and using them |
| WO2001080896A2 (en)* | 2000-04-21 | 2001-11-01 | Arch Development Corporation | Flavopiridol drug combinations and methods with reduced side effects |
| Publication number | Publication date |
|---|---|
| WO2002022133A1 (en) | 2002-03-21 |
| US20050004007A1 (en) | 2005-01-06 |
| Publication | Publication Date | Title |
|---|---|---|
| AU2001287157A1 (en) | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents | |
| AU2001270260A1 (en) | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | |
| AU2728201A (en) | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | |
| AU2001278070A1 (en) | Basal cell markers in breast cancer and uses thereof | |
| AU2001259758A1 (en) | Interleukin-1 inhibitors in the treatment of diseases | |
| AU2003284242A1 (en) | Methods and compositions for use in treating cancer | |
| AU2002227300A1 (en) | Reducing cellular damage in the human body | |
| IL156131A0 (en) | Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors | |
| AU2001244355A1 (en) | Heterobiarylsulphonamides and their use as pde 7 inhibitors | |
| AU2002338806A1 (en) | Pharmaceutical combinations of pde-v inhibitors and other agents | |
| AU2003256410A1 (en) | COMBINATION THERAPY WITH p38 MAP KINASE INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS | |
| AU2001260847A1 (en) | Compositions isolated from skin cells and methods for their use | |
| AU2002315168A1 (en) | Combination therapy of gamma-interferon and b cell specific antibodies | |
| AU2002230836A1 (en) | Benzylamine derivatives and their use as thrombin inhibitors | |
| AU5066900A (en) | Benzimidazole derivatives and their use as methionyl t-rna synthetase inhibitors | |
| AU2003298937A1 (en) | Heterocyclic compounds, methods of making them and their use in therapy | |
| AU4642600A (en) | Methods and compositions for use in potentiating antigen presentation by antigenpresenting cells | |
| AU1453301A (en) | Methods of reversing drug resistance in cancer cells | |
| AU2001258381A1 (en) | Use of parp inhibitors in cosmetic preparations | |
| AU2001271266A1 (en) | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes | |
| AU2002256347A1 (en) | Compositions and methods for the identification of protein interactions in vertebrate cells | |
| AU2000237154A1 (en) | Method for detecting and killing epithelial cancer cells | |
| AU2881301A (en) | Cancer cell implantation inhibitors | |
| AU2003257043A1 (en) | Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors | |
| AU2001255696A1 (en) | Telomerase inhibitors and methods of their use |